鑫达医学翻译公司-最好的医学翻译、病历翻译、药学翻译、sci论文翻译、生物翻译网站!您最好的医学论文翻译合作伙伴!
设为首页 | 加入收藏 | 联系我们
首页 > 翻译讲堂 >

医学翻译作品展示

发布者:鑫达医学翻译 发布时间:2011-12-22阅读:

Abstract
Background
Treatment of latent tuberculosis in patients infected with the human immunodeficiency virus (HIV) is efficacious, but few patients around the world receive such treatment. We evaluated three new regimens for latent tuberculosis that may be more potent and durable than standard isoniazid treatment.
Methods
We randomly assigned South African adults with HIV infection and a positive tuberculin skin test who were not taking antiretroviral therapy to receive rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks, rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks, isoniazid (300 mg) daily for up to 6 years (continuous isoniazid), or isoniazid (300 mg) daily for 6 months (control group). The primary end point was tuberculosis-free survival.
Results
The 1148 patients had a median age of 30 years and a median CD4 cell count of 484 per cubic millimeter. Incidence rates of active tuberculosis or death were 3.1 per 100 person-years in the rifapentine–isoniazid group, 2.9 per 100 person-years in the rifampin–isoniazid group, and 2.7 per 100 person-years in the continuous-isoniazid group, as compared with 3.6 per 100 person-years in the control group (P>0.05 for all comparisons). Serious adverse reactions were more common in the continuousisoniazid group (18.4 per 100 person-years) than in the other treatment groups (8.7 to 15.4 per 100 person-years). Two of 58 isolates of Mycobacterium tuberculosis (3.4%) were found to have multidrug resistance.
Conclusions
On the basis of the expected rates of tuberculosis in this population of HIV-infected adults, all secondary prophylactic regimens were effective. Neither a 3-month course of intermittent rifapentine or rifampin with isoniazid nor continuous isoniazid was superior to 6 months of isoniazid.

摘要
背景
艾滋病病毒感染者合并潜伏性结核患者可接受有效治疗,但全球接受该治疗的患者并不多。 本文对三种潜伏性结核治疗的新方案进行评估,并与异烟肼治疗进行比较。
方法
本文纳入来自南非感染HIV、结核菌素皮试阳性且未接受抗病毒治疗的成年患者。患者随机接受如下治疗:1)利福喷汀(900mg)联合异烟肼(900mg),一周1次,12周;2)利福平(600mg)联合异烟肼(900mg),一周2次,12周;3)持续服用异烟肼(每天300mg),6年;4)服用异烟肼(每天300mg),6个月(对照组)。研究主要预后为无结核生存率。
结果
纳入的1148名患者年龄中位数为30周岁,平均CD4T细胞为484/mm3。利福喷汀-异烟肼组活动性结核发病率或死亡率为3.1%,利福平-异烟肼组为2.9%,长期服用异烟肼组为2.7%,对照组为3.6%。组间统计无差异(P>0.05)。持续服用异烟肼组发生恶性不良反应的机率为18.4%,高于其他治疗组(8.7-15.4%)。临床分离出2株结核分子杆菌(3.4%,总58株)存在多重耐药性。
结论
根据该研究艾滋病感染者预期结核发生率,第二套预防方案是有效的。间歇性利福喷丁(或利福平)联合异烟肼或连续性异烟肼均比对照组(服用异烟肼6个月)有效。
 


鑫达医学翻译公司本着“专业、专注、诚信、共赢”的原则,旨在为广大客户提供生物学、医学、药学材料的口译与笔译,业务范围为医学英语翻译病历翻译医学文献翻译药学翻译SCI医学论文翻译以及写作与投稿,宣传册制作,项目申报材料及医疗类中英文网站的建设工作。
联系方式

免费咨询电话:400-6870-112
传真:0531-88956115
地址:山东省济南市高新区舜华路2000号舜泰广场6号楼27层CD区
邮箱: trans@xdtrans.com